P4‐250: Appraisal of the utility of the amyloid imaging taskforce recommendations for amyloid‐PET prescription

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care

Introduction

The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established.

Methods

Fifty-three cognitively impaired patients with clinical F¹⁸-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate.

Results

Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group.

Discussion

The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.

•

Both AUC-consistent and AUC-inconsistent patients benefit from amyloid imaging.

•

The greatest benefit in early-onset patients is confirming the suspected etiology.

•

The greatest benefit in late-onset patients is detecting amyloid-negative cases.